While a high rate of recreational drug use (RDU) has been documented among HIV-infected outpatients, particularly in men who have sex with men (MSM), there is a distinct lack of data for HIV-infected in-patients. Hospital admission offers a unique opportunity to engage drug users. We aimed to establish and characterize RDU among new admissions to a large dedicated London HIV in-patient unit and compare it to RDU among general medical admissions to inform clinical pathways.
Introduction
Recreational drug use (RDU) is increasingly prevalent among HIV-infected individuals across Europe and the UK [1] . A surge in RDU has been seen in men who have sex with men (MSM), who are more likely to use drugs for the purpose of sexual enhancement ("chemsex"), particularly methamphetamine, mephedrone and gamma butyrolactone/gamma hydroxybutyrate (GBL/GHB) [2] [3] [4] . London lesbian-bi-gay-trans (LBGT) drug support services have reported increases in methamphetamine use among clients from 3% in 2005 to 85% in 2013, 75% of clients being HIV infected [5] . Drug use facilitates long sexual sessions, often with multiple partners, increasing the likelihood of sexually transmitted infections (STIs) [6] . Methamphetamines, especially, have been associated with condomless sex with casual partners, including those of discordant HIV status, as reported in the 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) Study [3] . Additionally, there are reports of increasing polydrug use (more than one drug in the same time period) [3, 7] and injecting drug use among MSM [5, 8] , which further raise important public health concerns and pose substantial threats to HIV/hepatitis C virus (HCV) treatment and prevention efforts. Several key risk factors have been identified for RDU, ranging from situational and social factors (e.g. "club drug" use normalization in social venues) to psychological and personal factors (e.g. gender role uncertainty, homophobia and isolation) [9, 10] .
MSM users, particularly those who "slam" (inject chems), frequently do not identify as addicts or injecting drug users (IDUs) in the traditional sense [5] , which often leads to impaired engagement with medical care or addiction services [1] .
Data reveal higher rates of lifetime RDU relative to the general population among sexual health clinic attendees [6, 11] and HIV-positive MSM attending out-patient clinics [1, 3] . However, there is a distinct lack of data regarding RDU among the HIV-infected in-patient population. This is particularly important as hospital admission offers a unique but often neglected opportunity to identify and engage drug users with support services. We aimed to:
• characterize self-reported RDU among new admissions to a dedicated London HIV in-patient unit;
• establish the prevalence of recent RDU among HIVinfected admissions measured objectively through urine toxicology testing;
• compare the prevalence and type of RDU in HIVinfected in-patients to that in a control group of general medical admissions and that in the HIV/sexual health clinic populations described in the current literature.
Methods
A prospective opt-out physician-administered survey was completed for all new admissions to London's largest HIV in-patient unit over a 10-week period from 27 October 2014 to 4 January 2015 and for all new admissions to the medical acute assessment unit (AAU) in the same teaching hospital over two separate 24-h periods (7/8 October 2014 and 13/14 January 2015). The data collection period for each group was chosen to match group sizes. Data collected were age, gender, sexuality, past and/or current RDU (type, route and sexualized use), reason for admission, hepatitis B and C status and contact with drug services. HIV parameters, antiretroviral therapy (ART) status and adherence to ART were also recorded for the HIVinfected group. Adherence was established through note review and/or the finding of persistent virological failure despite established ART prescription. ; all engaged with out-patient care. The AAU population was more likely than the HIV-infected inpatients': to be female and older (median age 70 years; IQR 47-82 years) (P < 0.0001). HIV-infected in-patients were more likely than non-HIV-infected in-patients': to report lifetime RDU (70 vs. 29%, respectively; P = 0.0001) and current RDU (41 vs. 10%, respectively; P = 0.0001) and to have a positive urine toxicology screen on admission (19 vs.2%, respectively; P = 0.0091). Ninety-two per cent of all patients with a positive urine toxicology screen admitted to recent RDU.
None of the general medical patients disclosed sexualized or injecting drug use, whereas, of the 26 HIVinfected in-patients reporting current RDU, half reported chemsex (n = 13; 31% of all MSM admissions), half polydrug use (n = 13) and one-third use of injecting drugs (n = 9). Of the 13 MSM reporting chemsex, five admitted to slamming (injecting drug use associated with sex events).
Overall, 77% (20 of 26) of HIV-positive current recreational drug users reported use in the last month (representing 34% of all HIV-positive admissions; 20 of 59). Twenty-seven per cent had used in the last 24 h, 15% in the last week and 35% more than a week ago but in the last month. Only seven of 26 HIV-infected current recreational drug users (27%) were known to drug services: three were heterosexual IDUs receiving support from local Drug and Alcohol services but still actively injecting and the remaining four were MSM receiving specialist LBGT drug support (two were receiving promising treatment for their drug use and two were poorly compliant with drug support).
Recreational drug users were less likely to be on ART than non-users (70 vs.87%, respectively), and there was a trend for poorer adherence if on ART (67 vs.76%, respectively), although neither difference reached statistical significance. There was no difference in CD4 count between the two groups (Table 1b) .
RDU in HIV-infected in-patients: MSM (n = 42) vs. non-MSM (n = 17)
Crystal methamphetamine, mephedrone, GBL/GHB and/or ketamine were exclusively taken by MSM (11/42, P = 0.0103; Fig. 1a ). This is in keeping with recognized patterns of drug use in a sexual context among MSM [10] . Non-MSM were more likely to use cocaine, marijuana and heroin, although this did not reach statistical significance.
Hepatitis status in the HIV-infected in-patient group
No AAU patient had a known diagnosis of viral hepatitis, although this is a less tested population. Among the HIVinfected in-patients, 13 (22%) had a history of HCV infection [current, n = 9 (new on admission, n = 2); past, n = 4]; all except one (92%) reported current or past RDU. Eighteen (31%) patients were coinfected (n = 3) or had a past infection (n = 15) with hepatitis B virus (HBV), of whom 12 (67%) had a history of RDU (Fig. 1b) . Drug-related admissions in HIV-infected in-patients (n = 9)
Fifteen per cent of admissions to the HIV unit over 10 weeks were directly related to RDU (n = 9). Most were related to infection (endocarditis, n = 2; cellulitis/abscess, n = 2; infective diarrhoea, n = 1; acute HCV infection, n = 1), one was because of drug-related psychosis and two were because of drug-associated dyspnoea.
Discussion
This is the first published report describing RDU among HIV-infected in-patients. Our survey is unique in the use of urine toxicology to provide objective evidence of recent RDU as a comparator to self-reporting. These data are important, as the UK has seen growing and changing trends in substance misuse and its consequences among people living with HIV (PLWHIV) in the last 10 years [5, 10] . We report high rates of lifetime and current RDU among HIV-infected in-patients, particularly among MSM. Almost 80% of all in-patient recreational drug users had used in the last month (19% of all admissions had a positive urine toxicology screen). These rates were much higher than seen in the general medical admission population, which emphasizes the importance of a targeted RDU history on admission in the HIV-infected population. Most patients with a positive urine toxicology screen had admitted to recent RDU, suggesting that patients are honest about RDU when asked in a nonjudgemental and supportive manner [10, 11] . The six patients who declined a urine toxicology screen had reported RDU in the last 48 h and were likely to have tested positive.
Our data on current RDU among in-patient MSM (45%) are consistent with rates reported among MSM HIVinfected out-patients in the ASTRA study (44%) [3] and greater than found among MSM general sexual health clinic attendees (30-32%) [6, 11] .
Sexualized drug-taking among MSM is well described [8, 10] . In our cohort, chemsex was exclusively reported by MSM, with 31% of MSM HIV-infected in-patients admitting to it and a quarter reporting current crystal meth, GHB/GBL, mephedrone and/or ketamine use, which is higher than seen in the ASTRA study. This is important, as a higher prevalence of high-risk sexual behaviour is now well documented with increasing RDU [6] , which is not attenuated by controlling for sociodemographic or HIV-related factors [3] . UK genitourinary services have seen increased STI and hepatitis C diagnoses among MSM [8] . Chemsex has been shown to be a predictor of future seroconversion [12] .
Fifteen per cent of HIV-infected in-patients reported current injecting drug use (12% of MSM), which is significantly higher than the 3% reported in the ASTRA study.
Fifteen per cent of all HIV-infected in-patient admissions during the study period were directly related to drug use, which is similar to rates found in a retrospective note review in a different London hospital (13%) [13] . This reflects the health risks associated with RDU, which range from overdose to infection secondary to injecting or acquisition of STIs. The former is particularly salient to GHB/GBL, which has a narrow therapeutic range [4] . Evidence of further potential harmful effects of RDU has been documented. In the Swiss Cohort, noninjecting RDU was associated with higher rates of allcause mortality, depression and loss to follow-up [14] . Furthermore, crystal meth use in HIV-infected individuals has been associated with an increase in T-cell immune activation/proliferation and higher levels of proviral HIV DNA [15] .
There was a trend towards a lower likelihood of being on treatment and higher rates of virological failure if on therapy among recreational drug users in our cohort (overall and in MSM). This is in keeping with findings in the ASTRA study [3] . The Swiss HIV Cohort Study, interestingly, also found this to be the case in patients currently injecting drugs but not in noninjecting drug users [14] . CD4 counts were similar in the two groups within our cohort.
Thirteen patients (22%) admitted to our HIV unit had current or past hepatitis C. This is higher than the nationally reported HIV/HCV coinfection rate (8%) [16] . Twelve of the 13 had a history of RDU and two patients were newly diagnosed with HCV infection on admission.
There are limitations to our study. We compared our HIV-infected in-patient population with a general medical admission group with different demographics. An age-and gender-matched cohort comparison would be appropriate for future research. Additional studies using an age-matched HIV-negative MSM comparator group would provide necessary data for recommendations to extend screening to all MSM in-patients regardless of HIV status.
Our urine toxicology screen only tested for five compounds. One of these is morphine, the test for which cannot distinguish recent heroin use from prescribed opiates, limiting its utility. In our analysis, all morphine-positive toxicology screens were excluded (n = 13), as all were for patients on prescribed opiates. Additionally, all patients who declined urine toxicology screening had admitted to recent RDU. The urine toxicology screen data are therefore likely to be an underestimation. We did not ask patients about use of other recreational drugs, particularly nitrites and erectile dysfunction drugs, often used in a sexual context, and our survey was completed by the admitting physician, which may have led to RDU underreporting compared with self-reported surveys. Overall, this means that RDU rates may have been underestimated. Nevertheless, our survey findings did have good concordance with the urine toxicology results. Our numbers were small and from one centre only; a larger multicentre analysis including centres outside of London in the UK and other countries would be useful to define the extent of this problem and better characterize it.
We have demonstrated high rates of RDU among HIVinfected in-patients, yet less than a third had contact with drug support services, despite all being engaged with HIV out-patient services. While national and European guidelines [17, 18] recommend yearly RDU history taking in PLWHIV, they do not specify the timing or place, and most surveillance and referrals occur in the out-patient setting. Our data suggest that in-patient screening is crucial. Hospital admission offers a unique opportunity for intervention in hard to reach groups. Most hospital admissions are not planned, which arguably further increases the chances of detecting drug use (as opposed to routine screening during planned outpatient visits). Furthermore, patients have more extensive contact with health care professionals in this setting and may be more receptive, especially if RDU has led to the admission. This is particularly relevant to users who do not identify as addicts or are ambivalent about change [5] .
A structured approach for identifying recreational drug use among HIV-infected in-patients is highly recommended to enable support and harm reduction in the community. We recommend that multidisciplinary clinicians routinely and systematically enquire about RDU on admission of HIV-infected in-patients, through a tailored proforma, for instance. If recreational drug use is identified, expedient measures of harm reduction should be taken, particularly in sex-associated RDU (information about HCV and other STI transmission, safer injection rules, basic principles of sex-toy hygiene, drug therapeutic range, etc.). Clinicians should consider establishing reliable referral pathways to local and national support resources. The UK has multiple support services for drug and alcohol misuse in PLWHIV, such as Antidote, Positively UK and the Terrence Higgins Trust. Resources are accessible online and patients can self-refer, thereby optimizing access.
Resources
Antidote London Friend: http://londonfriend.org.uk/getsupport/drugsandalcohol/antidote-accessing-our-services/ Terence Higgins Trust: www.tht.org.uk Positively UK: www.positivelyuk.org
